
Arrowhead Pharmaceuticals ARWR
$ 70.74
2.34%
Annual report 2025
added 11-25-2025
Arrowhead Pharmaceuticals Cost of Revenue 2011-2026 | ARWR
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Arrowhead Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 17.3 M | 19.5 M | 16.6 M | 12.8 M | 6.67 M | 6.41 M | 1.41 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.5 M | 1.41 M | 11.5 M |
Quarterly Cost of Revenue Arrowhead Pharmaceuticals
| 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.99 M | - | 3.42 M | 3.58 M | 4.28 M | 12.3 M | 4.11 M | 4.28 M | 3.92 M | 10.3 M | 3.57 M | 3.92 M | 3.15 M | 7.63 M | 2.45 M | 3.15 M | 2.08 M | 5.01 M | 1.65 M | 2.08 M | 1.63 M | 4.99 M | 1.65 M | 1.63 M | 1.32 M | 1.09 M | 354 K | 1.32 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.3 M | 354 K | 3.66 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
15.3 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M | ||
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
ANI Pharmaceuticals
ANIP
|
250 M | $ 81.6 | -0.49 % | $ 1.58 B | ||
|
Amgen
AMGN
|
12.9 B | $ 342.65 | -0.08 % | $ 184 B | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
Aytu BioScience
AYTU
|
20.6 M | $ 2.63 | 1.74 % | $ 16.5 M | ||
|
Biogen
BIIB
|
2.31 B | $ 178.24 | 1.2 % | $ 26 B | ||
|
Ascendis Pharma A/S
ASND
|
3.52 M | $ 225.36 | 0.63 % | $ 5 B | ||
|
BioNTech SE
BNTX
|
2.91 B | $ 114.18 | -2.22 % | $ 27.2 B | ||
|
CASI Pharmaceuticals
CASI
|
12.6 M | $ 0.99 | -0.01 % | $ 135 M | ||
|
Aeterna Zentaris
AEZS
|
90 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
Catalyst Biosciences
CBIO
|
4.64 M | $ 9.63 | -5.08 % | $ 634 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
436 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | ||
|
Amneal Pharmaceuticals
AMRX
|
1.77 B | $ 13.65 | -3.3 % | $ 4.22 B | ||
|
AIkido Pharma
AIKI
|
9 K | - | 1.93 % | $ 17.4 M | ||
|
Cerus Corporation
CERS
|
33.4 M | $ 2.32 | -0.22 % | $ 428 M | ||
|
CureVac N.V.
CVAC
|
238 M | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | ||
|
Baudax Bio
BXRX
|
7.01 M | - | 0.59 % | $ 63 K |